HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
128:@0.078769:0.033217:0.109813:0.033217:0.109813:0.013052:0.078769:0.013052:0.010348:0.010348:0.010348
second-line therapy in an Art-experienced  :@0.076190:0.086287:0.442071:0.086287:0.442071:0.067956:0.076190:0.067956:0.008735:0.010751:0.010751:0.010751:0.010079:0.011087:0.007056:0.004032:0.004032:0.010079:0.010751:0.004704:0.005040:0.010079:0.010751:0.005376:0.011087:0.011087:0.009743:0.004704:0.004032:0.010079:0.004704:0.011087:0.010079:0.004704:0.012431:0.009743:0.007056:0.007056:0.010751:0.009407:0.011087:0.010751:0.005376:0.004032:0.010751:0.010079:0.010751:0.010751:0.011087:0.004704:0.004704
HiV-infected patient:@0.076190:0.101720:0.240148:0.101720:0.240148:0.083388:0.076190:0.083388:0.011423:0.004704:0.011759:0.007056:0.004032:0.010079:0.004704:0.010751:0.010751:0.005040:0.010751:0.011087:0.004704:0.011087:0.011087:0.005040:0.004032:0.010751:0.010079:0.005040
A switch to a second-line regimen must occur once a :@0.076190:0.118050:0.485100:0.118050:0.485100:0.102268:0.076190:0.102268:0.011188:0.005564:0.005866:0.012564:0.003024:0.005125:0.009782:0.009223:0.005564:0.005125:0.009903:0.005564:0.010326:0.005579:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.005564:0.004551:0.009827:0.010160:0.003024:0.014182:0.009827:0.009223:0.005564:0.014182:0.009192:0.005866:0.005125:0.005564:0.009903:0.009782:0.009782:0.009192:0.004551:0.005564:0.009903:0.009223:0.009782:0.009827:0.005564:0.010326:0.004188
second viral load is confirmed to be >1 000 copies/ml :@0.076190:0.132205:0.485130:0.132205:0.485130:0.116422:0.076190:0.116422:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005821:0.008376:0.003024:0.004551:0.010326:0.003024:0.005836:0.003024:0.009903:0.010326:0.010357:0.005836:0.003024:0.005866:0.005836:0.009782:0.009903:0.009223:0.003681:0.003681:0.004551:0.014182:0.009827:0.010341:0.005821:0.005125:0.009903:0.005821:0.010311:0.009827:0.005821:0.009162:0.008376:0.005836:0.008376:0.008376:0.008376:0.005836:0.009782:0.009903:0.010311:0.003024:0.009827:0.005866:0.006607:0.014182:0.003024:0.004188
taken one to three months apart, despite maximum ad-:@0.076190:0.146360:0.480942:0.146360:0.480942:0.130577:0.076190:0.130577:0.005125:0.010326:0.007590:0.009827:0.009223:0.003674:0.009903:0.009223:0.009827:0.003674:0.005125:0.009903:0.003674:0.005125:0.009223:0.004551:0.009827:0.009827:0.003674:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.003674:0.010326:0.010311:0.010326:0.004551:0.005125:0.004188:0.003674:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.003674:0.014182:0.010326:0.007257:0.003024:0.014182:0.009192:0.014182:0.003674:0.010326:0.010357:0.005020
herence.:@0.076190:0.160514:0.142639:0.160514:0.142639:0.144732:0.076190:0.144732:0.009223:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.004188
5:@0.142624:0.155214:0.147482:0.155214:0.147482:0.146060:0.142624:0.146060:0.004858
Guidelines currently  recommend  ritonavir-boosted :@0.090476:0.174667:0.485143:0.174667:0.485143:0.158884:0.090476:0.158884:0.013184:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.011445:0.009782:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.003024:0.008104:0.004188:0.007242:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.004188:0.007242:0.004551:0.003024:0.005125:0.009903:0.009223:0.010326:0.008376:0.003024:0.004551:0.005020:0.010311:0.009903:0.009903:0.005866:0.005125:0.009827:0.010357:0.004188
pIs with 2 NRTIs as second-line therapy in patients who :@0.076189:0.188822:0.485128:0.188822:0.485128:0.173039:0.076189:0.173039:0.008950:0.003417:0.005866:0.005624:0.012564:0.003024:0.005125:0.009223:0.005624:0.008376:0.005624:0.011188:0.009177:0.006441:0.003417:0.005866:0.005624:0.010326:0.005866:0.005624:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.005624:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.005624:0.003024:0.009223:0.005624:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005624:0.012564:0.009223:0.009903:0.004188
were on an InSTI-based first-line regimen for >2 years (a :@0.076189:0.202976:0.485128:0.202976:0.485128:0.187194:0.076189:0.187194:0.012564:0.009827:0.004551:0.009827:0.004717:0.009903:0.009223:0.004717:0.010326:0.009223:0.004717:0.003417:0.009223:0.007529:0.006441:0.003417:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.004717:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004717:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004702:0.004747:0.009903:0.004551:0.004702:0.009162:0.008376:0.004717:0.008104:0.009827:0.010326:0.004551:0.005866:0.004717:0.005579:0.010326:0.004188
resistance  test  may be  required)  or  patients previous-:@0.076189:0.217131:0.480940:0.217131:0.480940:0.201348:0.076189:0.201348:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.002389:0.005125:0.009827:0.005866:0.005125:0.004188:0.002389:0.014182:0.010326:0.008104:0.006592:0.010311:0.009827:0.004188:0.002389:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.009827:0.010357:0.005579:0.004188:0.002389:0.009903:0.004551:0.004188:0.002389:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006592:0.010311:0.004551:0.009827:0.008376:0.003024:0.009903:0.009192:0.005866:0.005020
ly on a NNRTI-based first-line regimen for whom DTG is :@0.076189:0.231286:0.485113:0.231286:0.485113:0.215503:0.076189:0.215503:0.003024:0.008104:0.005821:0.009903:0.009223:0.005821:0.010326:0.005821:0.011188:0.011188:0.009177:0.006441:0.003417:0.005020:0.010296:0.010326:0.005866:0.009827:0.010357:0.005821:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005821:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.005821:0.004747:0.009903:0.004551:0.005821:0.012564:0.009223:0.009903:0.014182:0.005821:0.011249:0.006441:0.013184:0.005821:0.003024:0.005866:0.004188
unsuitable (a resistance test is not required).  patients :@0.076189:0.245440:0.485142:0.245438:0.485142:0.229655:0.076189:0.229658:0.009192:0.009223:0.005866:0.009192:0.003024:0.005125:0.010326:0.010311:0.003024:0.009827:0.005745:0.005579:0.010326:0.005745:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.005745:0.005125:0.009827:0.005866:0.005125:0.005745:0.003024:0.005866:0.005745:0.009223:0.009903:0.005125:0.005745:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.009827:0.010357:0.005579:0.004188:0.012154:0.005745:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.527831
5,6:@0.405594:0.240139:0.417739:0.240139:0.417739:0.230985:0.405594:0.230985:0.004858:0.002429:0.004858
previously on a NNRTI-based first-line regimen for whom :@0.076187:0.259592:0.485157:0.259592:0.485157:0.243810:0.076187:0.243810:0.010311:0.004551:0.009827:0.008376:0.003024:0.009903:0.009192:0.005866:0.003024:0.008104:0.004460:0.009903:0.009223:0.004445:0.010326:0.004445:0.011188:0.011188:0.009177:0.006441:0.003417:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.004445:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004445:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004445:0.004747:0.009903:0.004551:0.004445:0.012564:0.009223:0.009903:0.014182:0.004188
DTG is suitable (resistance test not  required) may be :@0.076187:0.273747:0.485127:0.273747:0.485127:0.257964:0.076187:0.257964:0.011249:0.006441:0.013184:0.007393:0.003024:0.005866:0.007393:0.005866:0.009192:0.003024:0.005125:0.010326:0.010311:0.003024:0.009827:0.007393:0.005579:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.007393:0.005125:0.009827:0.005866:0.005125:0.007393:0.009223:0.009903:0.005125:0.004188:0.003190:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.009827:0.010357:0.005579:0.007393:0.014182:0.010326:0.008104:0.007393:0.010311:0.009827:0.004188
changed to DTG, with two NRTIs as second-line thera-:@0.076187:0.287902:0.480954:0.287902:0.480954:0.272119:0.076187:0.272119:0.009782:0.009223:0.010326:0.009223:0.010175:0.009827:0.010357:0.005851:0.005125:0.009903:0.005851:0.011249:0.006441:0.013184:0.004188:0.005851:0.012564:0.003024:0.005125:0.009223:0.005851:0.005125:0.012564:0.009903:0.005851:0.011188:0.009177:0.006441:0.003417:0.005866:0.005851:0.010326:0.005866:0.005851:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.005851:0.005125:0.009223:0.009827:0.004551:0.010326:0.005020
py.  The protease inhibitors include atazanavir/ritonavir :@0.076187:0.302057:0.485138:0.302054:0.485138:0.286272:0.076187:0.286274:0.010311:0.008104:0.004188:0.004865:0.005125:0.006441:0.009223:0.009827:0.005125:0.010311:0.004551:0.009903:0.005125:0.009827:0.010326:0.005866:0.009827:0.005125:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005125:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.005125:0.010326:0.005125:0.010326:0.006426:0.010326:0.009223:0.010326:0.008376:0.003024:0.004551:0.006607:0.004551:0.003024:0.005125:0.009903:0.009223:0.010326:0.008376:0.003024:0.004551:0.453694
6:@0.098795:0.296756:0.103653:0.296756:0.103653:0.287602:0.098795:0.287602:0.004858
(ATV/r), or LpV/r. Boosting with low-dose ritonavir inhibits :@0.076184:0.316209:0.485154:0.316209:0.485154:0.300426:0.076184:0.300426:0.005579:0.011188:0.006441:0.010614:0.006607:0.004551:0.005579:0.004188:0.004067:0.009903:0.004551:0.004067:0.006985:0.008950:0.010614:0.006607:0.004551:0.004188:0.004067:0.008678:0.009903:0.009903:0.005866:0.005125:0.003024:0.009223:0.010175:0.004067:0.012564:0.003024:0.005125:0.009223:0.004067:0.003024:0.009903:0.012564:0.005020:0.010357:0.009903:0.005866:0.009827:0.004067:0.004551:0.003024:0.005125:0.009903:0.009223:0.010326:0.008376:0.003024:0.004551:0.004067:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.005866:0.004188
pI metabolism, thereby increasing the  pI plasma  con-:@0.076184:0.330364:0.480951:0.330364:0.480951:0.314581:0.076184:0.314581:0.008950:0.003417:0.006562:0.014182:0.009827:0.005125:0.010326:0.010311:0.009903:0.003024:0.003024:0.005866:0.014182:0.004188:0.006562:0.005125:0.009223:0.009827:0.004551:0.009827:0.010311:0.008104:0.006562:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.003024:0.009223:0.010175:0.006562:0.005125:0.009223:0.009827:0.004188:0.002374:0.008950:0.003417:0.006562:0.010311:0.003024:0.010326:0.005866:0.014182:0.010326:0.004188:0.002389:0.009782:0.009903:0.009223:0.005020
centration and prolonging its half-life. If a patient was :@0.076184:0.344518:0.485138:0.344518:0.485138:0.328736:0.076184:0.328736:0.009782:0.009827:0.009223:0.005125:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.005972:0.010326:0.009223:0.010357:0.005987:0.010311:0.004551:0.009903:0.003024:0.009903:0.009223:0.010175:0.003024:0.009223:0.010175:0.005972:0.003024:0.005125:0.005866:0.005987:0.009223:0.010326:0.003024:0.004747:0.005020:0.003024:0.003024:0.004747:0.009827:0.004188:0.005987:0.003417:0.004747:0.005987:0.010326:0.005987:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005987:0.012564:0.010326:0.005866:0.004188
receiving a PI-based first-line regimen, second-line op:@0.076184:0.358673:0.475916:0.358673:0.475916:0.342891:0.076184:0.342891:0.004551:0.009827:0.009782:0.009827:0.003024:0.008376:0.003024:0.009223:0.010175:0.005700:0.010326:0.005700:0.008950:0.003417:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.005715:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005700:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004188:0.005700:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.005700:0.009903:0.010311
-:@0.475916:0.358673:0.480935:0.358673:0.480935:0.342891:0.475916:0.342891:0.005020
tions must be discussed with a specialist, as a genotype :@0.076184:0.372828:0.485123:0.372828:0.485123:0.357045:0.076184:0.357045:0.005125:0.003024:0.009903:0.009223:0.005866:0.004143:0.014182:0.009192:0.005866:0.005125:0.004143:0.010311:0.009827:0.004143:0.010357:0.003024:0.005866:0.009782:0.009192:0.005866:0.005866:0.009827:0.010357:0.004158:0.012564:0.003024:0.005125:0.009223:0.004143:0.010326:0.004143:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.005866:0.005125:0.004188:0.004158:0.010326:0.005866:0.004158:0.010326:0.004143:0.010175:0.009827:0.009223:0.009903:0.005125:0.008104:0.010311:0.009827:0.004188
resistance test may be required.:@0.076184:0.386983:0.310876:0.386983:0.310876:0.371200:0.076184:0.371200:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.005125:0.009827:0.005866:0.005125:0.004188:0.014182:0.010326:0.008104:0.004188:0.010311:0.009827:0.004188:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.009827:0.010357:0.004188
5:@0.310868:0.381680:0.315726:0.381680:0.315726:0.372527:0.310868:0.372527:0.004858
As boosted pIs are robust drugs, virological suppres-:@0.090476:0.401133:0.480955:0.401133:0.480955:0.385351:0.090476:0.385351:0.011188:0.005866:0.006259:0.010311:0.009903:0.009903:0.005866:0.005125:0.009827:0.010357:0.006274:0.008950:0.003417:0.005866:0.006274:0.010326:0.004551:0.009827:0.006259:0.004551:0.009903:0.010311:0.009192:0.005866:0.005125:0.006259:0.010357:0.004551:0.009192:0.010175:0.005866:0.004188:0.006259:0.008376:0.003024:0.004551:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.010326:0.003024:0.006274:0.005866:0.009192:0.010311:0.010311:0.004551:0.009827:0.005866:0.005020
sion will likely be achieved with good adherence, even :@0.076189:0.415288:0.485128:0.415288:0.485128:0.399505:0.076189:0.399505:0.005866:0.003024:0.009903:0.009223:0.004369:0.012564:0.003024:0.003024:0.003024:0.004385:0.003024:0.003024:0.007590:0.009827:0.003024:0.008104:0.004385:0.010311:0.009827:0.004369:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.010357:0.004369:0.012564:0.003024:0.005125:0.009223:0.004369:0.010175:0.009903:0.009903:0.010357:0.004369:0.010326:0.010357:0.009223:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.004188:0.004354:0.009827:0.008376:0.009827:0.009223:0.004188
if the two  NRTIs used in the  second-line regimen  are :@0.076189:0.429443:0.485143:0.429443:0.485143:0.413660:0.076189:0.413660:0.003024:0.004747:0.007439:0.005125:0.009223:0.009827:0.007439:0.005125:0.012564:0.009903:0.004188:0.003235:0.011188:0.009177:0.006426:0.003417:0.005866:0.007439:0.009192:0.005866:0.009827:0.010357:0.007439:0.003024:0.009223:0.007439:0.005125:0.009223:0.009827:0.004188:0.003235:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.007439:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004188:0.003235:0.010326:0.004551:0.009827:0.004188
compromised by resistance mutations.:@0.076189:0.443598:0.358627:0.443598:0.358627:0.427815:0.076189:0.427815:0.009782:0.009903:0.014182:0.010311:0.004551:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.004188:0.010311:0.008104:0.004188:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.014182:0.009192:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
5:@0.358617:0.438297:0.363475:0.438297:0.363475:0.429143:0.358617:0.429143:0.004858
NRTI  combinations for  second-line regimens include :@0.090476:0.457750:0.485128:0.457750:0.485128:0.441967:0.090476:0.441967:0.011188:0.009177:0.006441:0.003417:0.004188:0.002797:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.007000:0.004747:0.009903:0.004551:0.004188:0.002797:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.007000:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.005866:0.007000:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.004188
AZT plus 3TC, or TDF plus 3TC. 3TC can be re-used be-:@0.076189:0.471905:0.480971:0.471905:0.480971:0.456122:0.076189:0.456122:0.011188:0.007257:0.006441:0.005866:0.010311:0.003024:0.009192:0.005866:0.005881:0.008376:0.006441:0.012292:0.004188:0.005881:0.009903:0.004551:0.005866:0.006441:0.011249:0.007333:0.005881:0.010311:0.003024:0.009192:0.005866:0.005881:0.008376:0.006441:0.012292:0.004188:0.005881:0.008376:0.006441:0.012292:0.005881:0.009782:0.010326:0.009223:0.005881:0.010311:0.009827:0.005881:0.004551:0.009827:0.005020:0.009192:0.005866:0.009827:0.010357:0.005881:0.010311:0.009827:0.005020
cause it may have selected for the M184V resistance :@0.076189:0.486060:0.485128:0.486060:0.485128:0.470277:0.076189:0.470277:0.009782:0.010326:0.009192:0.005866:0.009827:0.006395:0.003024:0.005125:0.006395:0.014182:0.010326:0.008104:0.006395:0.009223:0.010326:0.008376:0.009827:0.006395:0.005866:0.009827:0.003024:0.009827:0.009782:0.005125:0.009827:0.010357:0.006395:0.004747:0.009903:0.004551:0.006395:0.005125:0.009223:0.009827:0.006395:0.013894:0.008376:0.008376:0.008376:0.010614:0.006410:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188
mutation and is partially able to restore susceptibility to :@0.076189:0.500214:0.485128:0.500214:0.485128:0.484432:0.076189:0.484432:0.014182:0.009192:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.004642:0.010326:0.009223:0.010357:0.004657:0.003024:0.005866:0.004657:0.010311:0.010326:0.004551:0.005125:0.003024:0.010326:0.003024:0.003024:0.008104:0.004672:0.010326:0.010311:0.003024:0.009827:0.004657:0.005125:0.009903:0.004642:0.004551:0.009827:0.005866:0.005125:0.009903:0.004551:0.009827:0.004642:0.005866:0.009192:0.005866:0.009782:0.009827:0.010311:0.005125:0.003024:0.010311:0.003024:0.003024:0.003024:0.005125:0.008104:0.004672:0.005125:0.009903:0.004188
AZT, d4T and TDF in the presence of thymidine analogue :@0.076189:0.514369:0.485143:0.514369:0.485143:0.498586:0.076189:0.498586:0.011188:0.007257:0.006441:0.004188:0.003462:0.010357:0.008376:0.006441:0.003477:0.010326:0.009223:0.010357:0.003477:0.006441:0.011249:0.007333:0.003462:0.003024:0.009223:0.003477:0.005125:0.009223:0.009827:0.003462:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.009782:0.009827:0.003462:0.009903:0.004747:0.003462:0.005125:0.009223:0.008104:0.014182:0.003024:0.010357:0.003024:0.009223:0.009827:0.003477:0.010326:0.009223:0.010326:0.003024:0.009903:0.010175:0.009192:0.009827:0.004188
mutations (TAMs). It is also able to restore susceptibility :@0.076189:0.528524:0.485113:0.528524:0.485113:0.512741:0.076189:0.512741:0.014182:0.009192:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.005458:0.005579:0.006441:0.011188:0.013894:0.005866:0.005579:0.004188:0.005458:0.003417:0.005125:0.005458:0.003024:0.005866:0.005473:0.010326:0.003024:0.005866:0.009903:0.005473:0.010326:0.010311:0.003024:0.009827:0.005473:0.005125:0.009903:0.005458:0.004551:0.009827:0.005866:0.005125:0.009903:0.004551:0.009827:0.005458:0.005866:0.009192:0.005866:0.009782:0.009827:0.010311:0.005125:0.003024:0.010311:0.003024:0.003024:0.003024:0.005125:0.008104:0.004188
to  TDF in  the  presence  of  the  K65R mutation.  Certain :@0.076189:0.542678:0.485128:0.542678:0.485128:0.526896:0.076189:0.526896:0.005125:0.009903:0.004188:0.002555:0.006441:0.011249:0.007333:0.006758:0.003024:0.009223:0.004188:0.002555:0.005125:0.009223:0.009827:0.004188:0.002555:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.009782:0.009827:0.004188:0.002555:0.009903:0.004747:0.004188:0.002555:0.005125:0.009223:0.009827:0.004188:0.002555:0.008935:0.008376:0.008376:0.009177:0.006758:0.014182:0.009192:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.002555:0.012292:0.009827:0.004551:0.005125:0.010326:0.003024:0.009223:0.004188
combinations are contra-indicated for toxicity reasons, :@0.076189:0.556833:0.485143:0.556833:0.485143:0.541050:0.076189:0.541050:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004989:0.010326:0.004551:0.009827:0.004974:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.004974:0.004747:0.009903:0.004551:0.004974:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.004989:0.004551:0.009827:0.010326:0.005866:0.009903:0.009223:0.005866:0.004188:0.004188
such d4T plus didanosine (ddI), or TDF plus ddI. TDF plus :@0.076189:0.570988:0.485113:0.570988:0.485113:0.555205:0.076189:0.555205:0.005866:0.009192:0.009782:0.009223:0.004687:0.010357:0.008376:0.006441:0.004687:0.010311:0.003024:0.009192:0.005866:0.004702:0.010357:0.003024:0.010357:0.010326:0.009223:0.009903:0.005866:0.003024:0.009223:0.009827:0.004687:0.005579:0.010357:0.010357:0.003417:0.005579:0.004188:0.004687:0.009903:0.004551:0.004687:0.006441:0.011249:0.007333:0.004687:0.010311:0.003024:0.009192:0.005866:0.004702:0.010357:0.010357:0.003417:0.004188:0.004687:0.006441:0.011249:0.007333:0.004687:0.010311:0.003024:0.009192:0.005866:0.004188
ABC are not  recommended  for  second-line ART,  as :@0.076189:0.585143:0.485128:0.585143:0.485128:0.569360:0.076189:0.569360:0.011188:0.008678:0.012292:0.008603:0.010326:0.004551:0.009827:0.008603:0.009223:0.009903:0.005125:0.004188:0.004400:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.004400:0.004747:0.009903:0.004551:0.004188:0.004400:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.008603:0.011188:0.009177:0.006441:0.004188:0.004188:0.004400:0.010326:0.005866:0.004188
these agents share several resistance mutations.  :@0.076189:0.599297:0.437730:0.599292:0.437730:0.583509:0.076189:0.583515:0.005125:0.009223:0.009827:0.005866:0.009827:0.004188:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004188:0.005866:0.009223:0.010326:0.004551:0.009827:0.004188:0.005866:0.009827:0.008376:0.009827:0.004551:0.010326:0.003024:0.004188:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.014182:0.009192:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004838:0.111863
5:@0.428682:0.593993:0.433541:0.593993:0.433541:0.584839:0.428682:0.584839:0.004858
If a patient defaults therapy, the same regimen should :@0.090476:0.613446:0.485113:0.613446:0.485113:0.597664:0.090476:0.597664:0.003417:0.004747:0.003266:0.010326:0.003266:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.003266:0.010357:0.009827:0.004747:0.010326:0.009192:0.003024:0.005125:0.005866:0.003266:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.003266:0.005125:0.009223:0.009827:0.003266:0.005866:0.010326:0.014182:0.009827:0.003266:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.003266:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188
be restarted, and if the viral load is not suppressed after :@0.076189:0.627601:0.485144:0.627601:0.485144:0.611818:0.076189:0.611818:0.010311:0.009827:0.004037:0.004551:0.009827:0.005866:0.005125:0.010326:0.004551:0.005125:0.009827:0.010357:0.004188:0.004037:0.010326:0.009223:0.010357:0.004037:0.003024:0.004747:0.004037:0.005125:0.009223:0.009827:0.004037:0.008376:0.003024:0.004551:0.010326:0.003024:0.004052:0.003024:0.009903:0.010326:0.010357:0.004052:0.003024:0.005866:0.004052:0.009223:0.009903:0.005125:0.004037:0.005866:0.009192:0.010311:0.010311:0.004551:0.009827:0.005866:0.005866:0.009827:0.010357:0.004052:0.010326:0.004747:0.005125:0.009827:0.004551:0.004188
three months, a switch to a second-line regimen should :@0.076189:0.641756:0.485144:0.641756:0.485144:0.625973:0.076189:0.625973:0.005125:0.009223:0.004551:0.009827:0.009827:0.004218:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.004188:0.004218:0.010326:0.004233:0.005866:0.012564:0.003024:0.005125:0.009782:0.009223:0.004233:0.005125:0.009903:0.004218:0.010326:0.004233:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.004218:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004218:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188
occur. If it was a d4T-based first-line regimen, AZT could :@0.076189:0.655910:0.485159:0.655910:0.485159:0.640128:0.076189:0.640128:0.009903:0.009782:0.009782:0.009192:0.004551:0.004188:0.004430:0.003417:0.004747:0.004430:0.003024:0.005125:0.004445:0.012564:0.010326:0.005866:0.004445:0.010326:0.004445:0.010357:0.008376:0.006441:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.004445:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004445:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004188:0.004430:0.011188:0.007257:0.006441:0.004430:0.009782:0.009903:0.009192:0.003024:0.010357:0.004188
be used as a substitute.  However,  TDF  should not  be :@0.076189:0.670065:0.485144:0.670065:0.485144:0.654283:0.076189:0.654283:0.010311:0.009827:0.007061:0.009192:0.005866:0.009827:0.010357:0.007061:0.010326:0.005866:0.007061:0.010326:0.007061:0.005866:0.009192:0.010311:0.005866:0.005125:0.003024:0.005125:0.009192:0.005125:0.009827:0.004188:0.004188:0.002857:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.004188:0.002857:0.006441:0.011249:0.007333:0.004188:0.002857:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.007061:0.009223:0.009903:0.005125:0.004188:0.002857:0.010311:0.009827:0.004188
substituted because if the patient has pre-existing NN-:@0.076189:0.684220:0.480956:0.684220:0.480956:0.668437:0.076189:0.668437:0.005866:0.009192:0.010311:0.005866:0.005125:0.003024:0.005125:0.009192:0.005125:0.009827:0.010357:0.005670:0.010311:0.009827:0.009782:0.010326:0.009192:0.005866:0.009827:0.005670:0.003024:0.004747:0.005670:0.005125:0.009223:0.009827:0.005655:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005670:0.009223:0.010326:0.005866:0.005670:0.010311:0.004551:0.009827:0.005020:0.009827:0.007257:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.005670:0.011188:0.011188:0.005020
RTI and 3TC resistance, TDF resistance may result, com-:@0.076189:0.698375:0.480971:0.698375:0.480971:0.682592:0.076189:0.682592:0.009177:0.006441:0.003417:0.004929:0.010326:0.009223:0.010357:0.004929:0.008376:0.006441:0.012292:0.004929:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.004929:0.006441:0.011249:0.007333:0.004929:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004929:0.014182:0.010326:0.008104:0.004929:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.004188:0.004914:0.009782:0.009903:0.014182:0.005020
promising its efficacy in second-line therapy. If a patient :@0.076189:0.712529:0.485128:0.712529:0.485128:0.696747:0.076189:0.696747:0.010311:0.004551:0.009903:0.014182:0.003024:0.005866:0.003024:0.009223:0.010175:0.003765:0.003024:0.005125:0.005866:0.003765:0.009827:0.004747:0.003681:0.003681:0.009782:0.010326:0.009782:0.008104:0.003765:0.003024:0.009223:0.003765:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.003765:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.003765:0.003417:0.004747:0.003765:0.010326:0.003765:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004188
has defaulted NNRTI-based first-line therapy many times :@0.076189:0.726684:0.485144:0.726684:0.485144:0.710901:0.076189:0.710901:0.009223:0.010326:0.005866:0.003855:0.010357:0.009827:0.004747:0.010326:0.009192:0.003024:0.005125:0.009827:0.010357:0.003855:0.011188:0.011188:0.009177:0.006441:0.003417:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.003855:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.003840:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.003840:0.014182:0.010326:0.009223:0.008104:0.003855:0.005125:0.003024:0.014182:0.009827:0.005866:0.004188
and if they are beyond the first year of ART, then a switch :@0.076189:0.740839:0.485144:0.740839:0.485144:0.725056:0.076189:0.725056:0.010326:0.009223:0.010357:0.003130:0.003024:0.004747:0.003130:0.005125:0.009223:0.009827:0.008104:0.003130:0.010326:0.004551:0.009827:0.003130:0.010311:0.009827:0.008104:0.009903:0.009223:0.010357:0.003130:0.005125:0.009223:0.009827:0.003130:0.003681:0.003681:0.004551:0.005866:0.005125:0.003130:0.008104:0.009827:0.010326:0.004551:0.003130:0.009903:0.004747:0.003130:0.011188:0.009177:0.006441:0.004188:0.003115:0.005125:0.009223:0.009827:0.009223:0.003130:0.010326:0.003130:0.005866:0.012564:0.003024:0.005125:0.009782:0.009223:0.004188
to a second-line ART should occur. This is because of the :@0.076189:0.754994:0.485144:0.754994:0.485144:0.739211:0.076189:0.739211:0.005125:0.009903:0.003508:0.010326:0.003523:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.003523:0.011188:0.009177:0.006441:0.003508:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003523:0.009903:0.009782:0.009782:0.009192:0.004551:0.004188:0.003508:0.006441:0.009223:0.003024:0.005866:0.003523:0.003024:0.005866:0.003523:0.010311:0.009827:0.009782:0.010326:0.009192:0.005866:0.009827:0.003523:0.009903:0.004747:0.003508:0.005125:0.009223:0.009827:0.004188
possibility of NNRTI resistance. Resistance testing is not :@0.076189:0.769148:0.485144:0.769148:0.485144:0.753366:0.076189:0.753366:0.010311:0.009903:0.005866:0.005866:0.003024:0.010311:0.003024:0.003024:0.003024:0.005125:0.008104:0.006305:0.009903:0.004747:0.006274:0.011188:0.011188:0.009177:0.006441:0.003417:0.006274:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.006274:0.009177:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.006274:0.005125:0.009827:0.005866:0.005125:0.003024:0.009223:0.010175:0.006274:0.003024:0.005866:0.006290:0.009223:0.009903:0.005125:0.004188
advised if the patient has been off ART for more than :@0.076189:0.783303:0.485113:0.783303:0.485113:0.767520:0.076189:0.767520:0.010326:0.010357:0.008376:0.003024:0.005866:0.009827:0.010357:0.005942:0.003024:0.004747:0.005942:0.005125:0.009223:0.009827:0.005927:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005942:0.009223:0.010326:0.005866:0.005942:0.010311:0.009827:0.009827:0.009223:0.005927:0.009903:0.004747:0.004747:0.005927:0.011188:0.009177:0.006441:0.005927:0.004747:0.009903:0.004551:0.005927:0.014182:0.009903:0.004551:0.009827:0.005927:0.005125:0.009223:0.010326:0.009223:0.004188
four weeks, as the resistance mutations will be achieved :@0.076189:0.797458:0.485113:0.797458:0.485113:0.781675:0.076189:0.781675:0.004747:0.009903:0.009192:0.004551:0.003523:0.012564:0.009827:0.009827:0.007590:0.005866:0.004188:0.003523:0.010326:0.005866:0.003538:0.005125:0.009223:0.009827:0.003523:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.003523:0.014182:0.009192:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.003523:0.012564:0.003024:0.003024:0.003024:0.003538:0.010311:0.009827:0.003523:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.010357:0.004188
by the presence of wild-type virus.  :@0.076189:0.811612:0.335175:0.811604:0.335175:0.795821:0.076189:0.795830:0.010311:0.008104:0.004188:0.005125:0.009223:0.009827:0.004188:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.009782:0.009827:0.004188:0.009903:0.004747:0.004188:0.012564:0.003024:0.003024:0.010357:0.005020:0.005125:0.008104:0.010311:0.009827:0.004188:0.008376:0.003024:0.004551:0.009192:0.005866:0.004188:0.004850:-0.063610
5:@0.326127:0.806305:0.330985:0.806305:0.330985:0.797151:0.326127:0.797151:0.004858
third-line therapy in an Art-experienced HiV-:@0.076190:0.842829:0.447783:0.842829:0.447783:0.824497:0.076190:0.824497:0.007056:0.010079:0.004032:0.005376:0.011087:0.007056:0.004032:0.004032:0.010079:0.010751:0.004704:0.005040:0.010079:0.010751:0.005376:0.011087:0.011087:0.009743:0.004704:0.004032:0.010079:0.004704:0.011087:0.010079:0.004704:0.012431:0.009743:0.007056:0.007056:0.010751:0.009407:0.011087:0.010751:0.005376:0.004032:0.010751:0.010079:0.010751:0.010751:0.011087:0.004704:0.011423:0.004704:0.011759:0.007056
infected patient failing any second-line regimen:@0.076190:0.858261:0.468613:0.858261:0.468613:0.839930:0.076190:0.839930:0.004032:0.010079:0.004704:0.010751:0.010751:0.005040:0.010751:0.011087:0.004704:0.011087:0.011087:0.005040:0.004032:0.010751:0.010079:0.005040:0.004704:0.004704:0.011087:0.004032:0.004032:0.004032:0.010079:0.011087:0.004704:0.011087:0.010079:0.009743:0.004704:0.007392:0.010751:0.010751:0.010751:0.010079:0.011087:0.007056:0.004032:0.004032:0.010079:0.010751:0.004704:0.005376:0.010751:0.011087:0.004032:0.015791:0.010751:0.010079
patients  must  be  offered  in-depth  adherence  counsel-:@0.076190:0.874592:0.480942:0.874592:0.480942:0.858809:0.076190:0.858809:0.008648:0.010024:0.004823:0.002721:0.009525:0.008920:0.004823:0.005564:0.004188:0.003402:0.013879:0.008890:0.005564:0.004823:0.004188:0.003402:0.010009:0.009525:0.004188:0.003402:0.009601:0.004445:0.004445:0.009525:0.004248:0.009525:0.010054:0.004188:0.003402:0.002721:0.008920:0.004717:0.010054:0.009525:0.010009:0.004823:0.008920:0.004188:0.003402:0.010024:0.010054:0.008920:0.009525:0.004248:0.009525:0.008920:0.009480:0.009525:0.004188:0.003402:0.009480:0.009601:0.008890:0.008920:0.005564:0.009525:0.002721:0.005020
ling prior to the application for, and initiation of, third-line :@0.076190:0.888747:0.485191:0.888747:0.485191:0.872964:0.076190:0.872964:0.002721:0.002721:0.008920:0.009873:0.004914:0.010009:0.004248:0.002721:0.009601:0.004248:0.004914:0.004823:0.009601:0.004914:0.004823:0.008920:0.009525:0.004914:0.010024:0.010009:0.010009:0.002721:0.002721:0.009480:0.010024:0.004823:0.002721:0.009601:0.008920:0.004914:0.004445:0.009601:0.004248:0.003886:0.004914:0.010024:0.008920:0.010054:0.004914:0.002721:0.008920:0.002721:0.004823:0.002721:0.010024:0.004823:0.002721:0.009601:0.008920:0.004914:0.009601:0.004445:0.003886:0.004914:0.004823:0.008920:0.002721:0.004248:0.010054:0.004717:0.002721:0.002721:0.008920:0.009827:0.004188
drugs. These patients require care under the supervision of :@0.076190:0.902901:0.485175:0.902901:0.485175:0.887119:0.076190:0.887119:0.010054:0.004248:0.008890:0.009873:0.005564:0.003886:0.003583:0.006138:0.008920:0.009525:0.005564:0.009525:0.003583:0.010009:0.010024:0.004823:0.002721:0.009525:0.008920:0.004823:0.005564:0.003583:0.004248:0.009525:0.010009:0.008890:0.002721:0.004248:0.009525:0.003583:0.009480:0.010024:0.004248:0.009525:0.003583:0.008890:0.008920:0.010054:0.009525:0.004248:0.003583:0.004823:0.008920:0.009525:0.003583:0.005564:0.008890:0.010009:0.009525:0.004248:0.008074:0.002721:0.005564:0.002721:0.009601:0.008920:0.003583:0.009601:0.004747:0.004188
a specialist. The choice of ART should be based on geno-:@0.076190:0.917056:0.481003:0.917056:0.481003:0.901273:0.076190:0.901273:0.010024:0.004158:0.005564:0.010009:0.009525:0.009480:0.002721:0.010024:0.002721:0.002721:0.005564:0.004823:0.003886:0.004158:0.006138:0.008920:0.009525:0.004158:0.009480:0.008920:0.009601:0.002721:0.009480:0.009525:0.004158:0.009601:0.004445:0.004158:0.010886:0.008875:0.006138:0.004158:0.005564:0.008920:0.009601:0.008890:0.002721:0.010054:0.004158:0.010009:0.009525:0.004158:0.010009:0.010024:0.005564:0.009525:0.010054:0.004158:0.009601:0.008920:0.004158:0.009873:0.009525:0.008920:0.009601:0.005020
type  resistance  testing.  These  drugs  are  very  expensive, :@0.076190:0.931211:0.485115:0.931211:0.485115:0.915428:0.076190:0.915428:0.004823:0.007801:0.010009:0.009525:0.004188:0.002283:0.004248:0.009525:0.005564:0.002721:0.005564:0.004823:0.010024:0.008920:0.009480:0.009525:0.004188:0.002283:0.004823:0.009525:0.005564:0.004823:0.002721:0.008920:0.009873:0.003886:0.004188:0.002283:0.006138:0.008920:0.009525:0.005564:0.009525:0.004188:0.002283:0.010054:0.004248:0.008890:0.009873:0.005564:0.004188:0.002283:0.010024:0.004248:0.009525:0.004188:0.002283:0.008074:0.009525:0.004248:0.007801:0.004188:0.002283:0.009525:0.006955:0.010009:0.009525:0.008920:0.005564:0.002721:0.008074:0.009525:0.004188:0.004188
but are now available in the state sector (see Table 3).  :@0.076190:0.945365:0.473608:0.945363:0.473608:0.929580:0.076190:0.929583:0.010009:0.008890:0.004823:0.003886:0.010024:0.004248:0.009525:0.003886:0.008920:0.009601:0.012262:0.003886:0.010024:0.008074:0.010024:0.002721:0.002721:0.010024:0.010009:0.002721:0.009525:0.003886:0.002721:0.008920:0.003886:0.004823:0.008920:0.009525:0.003886:0.005564:0.004823:0.010024:0.004823:0.009525:0.003886:0.005564:0.009525:0.009480:0.004823:0.009601:0.004248:0.003886:0.005277:0.005564:0.009525:0.009525:0.003886:0.006138:0.010024:0.010009:0.002721:0.009525:0.003886:0.008074:0.005277:0.004188:0.011474:-0.377203
5,6:@0.457623:0.940064:0.469417:0.940064:0.469417:0.930910:0.457623:0.930910:0.004683:0.002254:0.004858
ACute AnD CHrOniC tOxiCities:@0.519047:0.087643:0.811382:0.087643:0.811382:0.067478:0.519047:0.067478:0.013674:0.014413:0.011826:0.007761:0.009609:0.005174:0.013674:0.013674:0.012935:0.005174:0.014413:0.012566:0.010718:0.015522:0.013674:0.005174:0.014413:0.005174:0.007761:0.015522:0.012566:0.005174:0.014413:0.005174:0.007761:0.005174:0.009609:0.009609
Many drug reactions are mild and self-limiting and oc-:@0.519047:0.103581:0.923814:0.103581:0.923814:0.087798:0.519047:0.087798:0.013894:0.010326:0.009223:0.008104:0.005277:0.010357:0.004551:0.009192:0.010175:0.005277:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.005277:0.010326:0.004551:0.009827:0.005277:0.014182:0.003024:0.003024:0.010357:0.005277:0.010326:0.009223:0.010357:0.005277:0.005866:0.009827:0.003024:0.004747:0.005020:0.003024:0.003024:0.014182:0.003024:0.005125:0.003024:0.009223:0.010175:0.005292:0.010326:0.009223:0.010357:0.005277:0.009903:0.009782:0.005020
cur in the first few weeks of therapy. These include head:@0.519047:0.117735:0.918779:0.117735:0.918779:0.101953:0.519047:0.101953:0.009782:0.009192:0.004551:0.003235:0.003024:0.009223:0.003251:0.005125:0.009223:0.009827:0.003235:0.003681:0.003681:0.004551:0.005866:0.005125:0.003235:0.004747:0.009827:0.012564:0.003235:0.012564:0.009827:0.009827:0.007590:0.005866:0.003251:0.009903:0.004747:0.003235:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.003251:0.006441:0.009223:0.009827:0.005866:0.009827:0.003235:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.003251:0.009223:0.009827:0.010326:0.010357
-:@0.918779:0.117735:0.923799:0.117735:0.923799:0.101953:0.918779:0.101953:0.005020
ache, nausea and abdominal discomfort. More severe :@0.519047:0.131890:0.927987:0.131890:0.927987:0.116108:0.519047:0.116108:0.010326:0.009782:0.009223:0.009827:0.004188:0.004657:0.009223:0.010326:0.009192:0.005866:0.009827:0.010326:0.004672:0.010326:0.009223:0.010357:0.004672:0.010326:0.010311:0.010357:0.009903:0.014182:0.003024:0.009223:0.010326:0.003024:0.004672:0.010357:0.003024:0.005866:0.009782:0.009903:0.014182:0.004747:0.009903:0.004551:0.005125:0.004188:0.004657:0.013894:0.009903:0.004551:0.009827:0.004657:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.004188
side effects  can  occur  after  months  to  years  and  in-:@0.519047:0.146045:0.923799:0.146045:0.923799:0.130262:0.519047:0.130262:0.005866:0.003024:0.010357:0.009827:0.007151:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188:0.002948:0.009782:0.010326:0.009223:0.004188:0.002948:0.009903:0.009782:0.009782:0.009192:0.004551:0.004188:0.002948:0.010326:0.004747:0.005125:0.009827:0.004551:0.004188:0.002948:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.004188:0.002948:0.005125:0.009903:0.004188:0.002948:0.008104:0.009827:0.010326:0.004551:0.005866:0.004188:0.002948:0.010326:0.009223:0.010357:0.004188:0.002948:0.003024:0.009223:0.005020
clude anaemia, the hyperlactataemia syndromes, peri-:@0.519047:0.160200:0.923799:0.160200:0.923799:0.144417:0.519047:0.144417:0.009782:0.003024:0.009192:0.010357:0.009827:0.003750:0.010326:0.009223:0.010326:0.009827:0.014182:0.003024:0.010326:0.004188:0.003750:0.005125:0.009223:0.009827:0.003750:0.009223:0.008104:0.010311:0.009827:0.004551:0.003024:0.010326:0.009782:0.005125:0.010326:0.005125:0.010326:0.009827:0.014182:0.003024:0.010326:0.003765:0.005866:0.008104:0.009223:0.010357:0.004551:0.009903:0.014182:0.009827:0.005866:0.004188:0.003750:0.010311:0.009827:0.004551:0.003024:0.005020
pheral neuropathy and lipodystrophy. If toxicity does :@0.519047:0.174354:0.927987:0.174354:0.927987:0.158572:0.519047:0.158572:0.010311:0.009223:0.009827:0.004551:0.010326:0.003024:0.007393:0.009223:0.009827:0.009192:0.004551:0.009903:0.010296:0.010326:0.005125:0.009223:0.008104:0.007393:0.010326:0.009223:0.010357:0.007393:0.003024:0.003024:0.010311:0.009903:0.010357:0.008104:0.005866:0.005125:0.004551:0.009903:0.010311:0.009223:0.008104:0.004188:0.007393:0.003417:0.004747:0.007393:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.007393:0.010357:0.009903:0.009827:0.005866:0.004188
not resolve or is severe, the drug should be substituted. :@0.519047:0.188509:0.927987:0.188509:0.927987:0.172726:0.519047:0.172726:0.009223:0.009903:0.005125:0.004883:0.004551:0.009827:0.005866:0.009903:0.003024:0.008376:0.009827:0.004899:0.009903:0.004551:0.004883:0.003024:0.005866:0.004883:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.004188:0.004883:0.005125:0.009223:0.009827:0.004883:0.010357:0.004551:0.009192:0.010175:0.004883:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004883:0.010311:0.009827:0.004883:0.005866:0.009192:0.010311:0.005866:0.005125:0.003024:0.005125:0.009192:0.005125:0.009827:0.010357:0.004188:0.004188
The viral load must be suppressed before substituting a :@0.519047:0.202664:0.928002:0.202664:0.928002:0.186881:0.519047:0.186881:0.006441:0.009223:0.009827:0.004883:0.008376:0.003024:0.004551:0.010326:0.003024:0.004899:0.003024:0.009903:0.010326:0.010357:0.004899:0.014182:0.009192:0.005866:0.005125:0.004883:0.010311:0.009827:0.004899:0.005866:0.009192:0.010311:0.010311:0.004551:0.009827:0.005866:0.005866:0.009827:0.010357:0.004899:0.010311:0.009827:0.004747:0.009903:0.004551:0.009827:0.004883:0.005866:0.009192:0.010311:0.005866:0.005125:0.003024:0.005125:0.009192:0.005125:0.003024:0.009223:0.010175:0.004899:0.010326:0.004188
single drug,  otherwise  resistance  may develop to  the :@0.519047:0.216819:0.928017:0.216819:0.928017:0.201036:0.519047:0.201036:0.005866:0.003024:0.009223:0.010175:0.003024:0.009827:0.006925:0.010357:0.004551:0.009192:0.010175:0.004188:0.004188:0.002721:0.009903:0.005125:0.009223:0.009827:0.004551:0.012564:0.003024:0.005866:0.009827:0.004188:0.002721:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.002721:0.014182:0.010326:0.008104:0.006925:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.006925:0.005125:0.009903:0.004188:0.002721:0.005125:0.009223:0.009827:0.004188
new drug, affecting future regimens. single drug substi-:@0.519047:0.230973:0.923799:0.230973:0.923799:0.215191:0.519047:0.215191:0.009223:0.009827:0.012564:0.004672:0.010357:0.004551:0.009192:0.010175:0.004188:0.004672:0.010326:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.009223:0.010175:0.004672:0.004747:0.009192:0.005125:0.009192:0.004551:0.009827:0.004672:0.004551:0.009827:0.010160:0.003024:0.014182:0.009827:0.009223:0.005866:0.004188:0.004687:0.007529:0.003024:0.009223:0.010175:0.003024:0.009827:0.004687:0.010357:0.004551:0.009192:0.010175:0.004672:0.005866:0.009192:0.010311:0.005866:0.005125:0.003024:0.005020
tutions can be performed safely in the first six months of :@0.519047:0.245128:0.927987:0.245128:0.927987:0.229345:0.519047:0.229345:0.005125:0.009192:0.005125:0.003024:0.009903:0.009223:0.005866:0.004400:0.009782:0.010326:0.009223:0.004400:0.010311:0.009827:0.004400:0.010311:0.009827:0.004551:0.004747:0.009903:0.004551:0.014182:0.009827:0.010357:0.004400:0.005866:0.010326:0.004747:0.009827:0.003024:0.008104:0.004415:0.003024:0.009223:0.004400:0.005125:0.009223:0.009827:0.004400:0.003681:0.003681:0.004551:0.005866:0.005125:0.004400:0.005866:0.003024:0.007257:0.004415:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.004400:0.009903:0.004747:0.004188
ART without measuring the viral load.  Table 2 discusses :@0.519047:0.259283:0.927991:0.259336:0.927991:0.243554:0.519047:0.243500:0.011188:0.009177:0.006441:0.004657:0.012564:0.003024:0.005125:0.009223:0.009903:0.009192:0.005125:0.004657:0.014182:0.009827:0.010326:0.005866:0.009192:0.004551:0.003024:0.009223:0.010175:0.004657:0.005125:0.009223:0.009827:0.004657:0.008376:0.003024:0.004551:0.010326:0.003024:0.004672:0.003024:0.009903:0.010326:0.010357:0.004188:0.004887:0.004672:0.006441:0.010326:0.010311:0.003024:0.009827:0.004672:0.008376:0.004672:0.010357:0.003024:0.005866:0.009782:0.009192:0.005866:0.005866:0.009827:0.005866:0.066782
5:@0.790975:0.254038:0.795833:0.254038:0.795833:0.244884:0.790975:0.244884:0.004858
the toxicities.:@0.519051:0.273491:0.613560:0.273491:0.613560:0.257708:0.519051:0.257708:0.005125:0.009223:0.009827:0.004188:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.003024:0.009827:0.005866:0.004188
Art in PAtients WitH COmmOn infeCtiOns:@0.519047:0.306403:0.911538:0.306403:0.911538:0.286238:0.519047:0.286238:0.013674:0.010718:0.007761:0.005174:0.005174:0.013674:0.005174:0.010348:0.013674:0.007761:0.005174:0.009609:0.013674:0.007761:0.009609:0.005174:0.016631:0.005174:0.007761:0.012566:0.005174:0.014413:0.015522:0.016631:0.016631:0.015522:0.013674:0.005174:0.005174:0.013674:0.008870:0.009609:0.014413:0.007761:0.005174:0.015522:0.013674:0.009609
tuberculosis:@0.519047:0.322340:0.607947:0.322340:0.607947:0.305842:0.519047:0.305842:0.006350:0.009071:0.009979:0.009676:0.004838:0.009676:0.009071:0.003629:0.009676:0.006652:0.003629:0.006652
 – The decision to start ART in patients with :@0.607947:0.322340:0.928017:0.322340:0.928017:0.306558:0.607947:0.306558:0.005337:0.007560:0.005337:0.006441:0.009223:0.009827:0.005322:0.010357:0.009827:0.009782:0.003024:0.005866:0.003024:0.009903:0.009223:0.005337:0.005125:0.009903:0.005337:0.005866:0.005125:0.010326:0.004551:0.005125:0.005322:0.011188:0.009177:0.006441:0.005322:0.003024:0.009223:0.005337:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005337:0.012564:0.003024:0.005125:0.009223:0.004188
pulmonary or  extra-pulmonary  non-neurological  tu-:@0.519047:0.336495:0.923814:0.336495:0.923814:0.320712:0.519047:0.320712:0.010311:0.009192:0.003024:0.014182:0.009903:0.009223:0.010326:0.004551:0.008104:0.011490:0.009903:0.004551:0.004188:0.007287:0.009827:0.007257:0.005125:0.004551:0.010326:0.005020:0.010311:0.009192:0.003024:0.014182:0.009903:0.009223:0.010326:0.004551:0.008104:0.004188:0.007287:0.009223:0.009903:0.009223:0.005020:0.009223:0.009827:0.009192:0.004551:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.010326:0.003024:0.004188:0.007287:0.005125:0.009192:0.005020
berculosis (TB) is based on the CD4 count.  If the CD4 :@0.519047:0.350650:0.927978:0.350660:0.927978:0.334877:0.519047:0.334867:0.010311:0.009827:0.004551:0.009782:0.009192:0.003024:0.009903:0.005866:0.003024:0.005866:0.005261:0.005579:0.006441:0.008678:0.005579:0.005261:0.003024:0.005866:0.005261:0.010311:0.010326:0.005866:0.009827:0.010357:0.005261:0.009903:0.009223:0.005246:0.005125:0.009223:0.009827:0.005246:0.012292:0.011249:0.008376:0.005261:0.009782:0.009903:0.009192:0.009223:0.005125:0.004188:0.012117:0.005246:0.003417:0.004747:0.005246:0.005125:0.009223:0.009827:0.005246:0.012292:0.011249:0.008376:-0.052796
5,6:@0.831648:0.345361:0.843793:0.345361:0.843793:0.336207:0.831648:0.336207:0.004858:0.002429:0.004858
count is ≤50 cells/μl, the aim should be to start therapy :@0.519054:0.364814:0.927994:0.364814:0.927994:0.349032:0.519054:0.349032:0.009782:0.009903:0.009192:0.009223:0.005125:0.005004:0.003024:0.005866:0.005020:0.008300:0.008376:0.008376:0.005020:0.009782:0.009827:0.003024:0.003024:0.005866:0.006607:0.009223:0.003024:0.004188:0.005020:0.005125:0.009223:0.009827:0.005004:0.010326:0.003024:0.014182:0.005020:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005004:0.010311:0.009827:0.005020:0.005125:0.009903:0.005004:0.005866:0.005125:0.010326:0.004551:0.005125:0.005004:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188
after two weeks of TB treatment. However, if the CD4 :@0.519054:0.378969:0.927994:0.378969:0.927994:0.363186:0.519054:0.363186:0.010326:0.004747:0.005125:0.009827:0.004551:0.006244:0.005125:0.012564:0.009903:0.006244:0.012564:0.009827:0.009827:0.007590:0.005866:0.006259:0.009903:0.004747:0.006244:0.006441:0.008678:0.006244:0.005125:0.004551:0.009827:0.010326:0.005125:0.014167:0.009827:0.009223:0.005125:0.004188:0.006244:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.006244:0.003024:0.004747:0.006259:0.005125:0.009223:0.009827:0.006244:0.012292:0.011249:0.008376:0.004188
count  is  >50  cells/μl,  therapy  should  be  delayed  until :@0.519054:0.393124:0.927994:0.393124:0.927994:0.377341:0.519054:0.377341:0.009782:0.009903:0.009192:0.009223:0.005125:0.004188:0.002752:0.003024:0.005866:0.004188:0.002767:0.009162:0.008376:0.008376:0.004188:0.002767:0.009782:0.009827:0.003024:0.003024:0.005866:0.006607:0.009223:0.003024:0.004188:0.004188:0.002767:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.002752:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188:0.002752:0.010311:0.009827:0.004188:0.002752:0.010357:0.009827:0.003024:0.010326:0.008104:0.009827:0.010357:0.004188:0.002767:0.009192:0.009223:0.005125:0.003024:0.003024:0.004188
after the intensive phase of TB treatment, unless the pa-:@0.519054:0.407278:0.923821:0.407278:0.923821:0.391496:0.519054:0.391496:0.010326:0.004747:0.005125:0.009827:0.004551:0.004082:0.005125:0.009223:0.009827:0.004097:0.003024:0.009223:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.004097:0.010311:0.009223:0.010326:0.005866:0.009827:0.004097:0.009903:0.004747:0.004097:0.006441:0.008678:0.004097:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.004082:0.009192:0.009223:0.003024:0.009827:0.005866:0.005866:0.004097:0.005125:0.009223:0.009827:0.004097:0.010311:0.010326:0.005020
tient has other serious AIDs-related conditions. This de-:@0.519054:0.421433:0.923821:0.421433:0.923821:0.405650:0.519054:0.405650:0.005125:0.003024:0.009827:0.009223:0.005125:0.005624:0.009223:0.010326:0.005866:0.005624:0.009903:0.005125:0.009223:0.009827:0.004536:0.005624:0.005866:0.009827:0.004551:0.003024:0.009903:0.009192:0.005866:0.005624:0.011188:0.003417:0.011249:0.007529:0.005020:0.004551:0.009827:0.003024:0.010326:0.005125:0.009827:0.010357:0.005624:0.009782:0.009903:0.009223:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.005624:0.006441:0.009223:0.003024:0.005866:0.005624:0.010357:0.009827:0.005020
lay is expected to reduce the risk of drug interactions :@0.519054:0.435588:0.928009:0.435588:0.928009:0.419805:0.519054:0.419805:0.003024:0.010326:0.008104:0.006048:0.003024:0.005866:0.006048:0.009827:0.007257:0.010311:0.009827:0.009782:0.005125:0.009827:0.010357:0.006048:0.005125:0.009903:0.006048:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.006032:0.005125:0.009223:0.009827:0.006048:0.004551:0.003024:0.005866:0.007590:0.006048:0.009903:0.004747:0.006048:0.010357:0.004551:0.009192:0.010175:0.006048:0.003024:0.009223:0.005125:0.009827:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
and shared side effects of ART with TB therapy and the :@0.519054:0.449743:0.927978:0.449743:0.927978:0.433960:0.519054:0.433960:0.010326:0.009223:0.010357:0.004762:0.005866:0.009223:0.010326:0.004551:0.009827:0.010357:0.004762:0.005866:0.003024:0.010357:0.009827:0.004762:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004762:0.009903:0.004747:0.004762:0.011188:0.009177:0.006441:0.004762:0.012564:0.003024:0.005125:0.009223:0.004762:0.006441:0.008678:0.004762:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004762:0.010326:0.009223:0.010357:0.004762:0.005125:0.009223:0.009827:0.004188
risk of IRIs. In patients with TB meningitis, ART should be :@0.519054:0.463897:0.927994:0.463897:0.927994:0.448115:0.519054:0.448115:0.004551:0.003024:0.005866:0.007590:0.005352:0.009903:0.004747:0.005337:0.003417:0.009177:0.003417:0.007529:0.004188:0.005352:0.003417:0.009223:0.005337:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005352:0.012564:0.003024:0.005125:0.009223:0.005337:0.006441:0.008678:0.005337:0.014182:0.009827:0.009223:0.003024:0.009223:0.010175:0.003024:0.005125:0.003024:0.005866:0.004188:0.005337:0.011188:0.009177:0.006441:0.005337:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005352:0.010311:0.009827:0.004188
deferred  until four to eight weeks after the start of TB :@0.519054:0.478052:0.928009:0.478052:0.928009:0.462269:0.519054:0.462269:0.010357:0.009827:0.004747:0.009827:0.004551:0.004551:0.009827:0.010357:0.004188:0.002313:0.009192:0.009223:0.005125:0.003024:0.003024:0.006516:0.004747:0.009903:0.009192:0.004551:0.006516:0.005125:0.009903:0.006516:0.009827:0.003024:0.010175:0.009223:0.005125:0.006516:0.012564:0.009827:0.009827:0.007590:0.005866:0.006516:0.010326:0.004747:0.005125:0.009827:0.004551:0.006516:0.005125:0.009223:0.009827:0.006516:0.005866:0.005125:0.010326:0.004551:0.005125:0.006516:0.009903:0.004747:0.006516:0.006441:0.008678:0.004188
treatment.:@0.519054:0.492207:0.596554:0.492207:0.596554:0.476424:0.519054:0.476424:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188
5,6:@0.596532:0.486957:0.608677:0.486957:0.608677:0.477803:0.596532:0.477803:0.004858:0.002429:0.004858
EFV is the preferred NNRTI for use with rifampicin. NVp :@0.533333:0.506415:0.927985:0.506415:0.927985:0.490632:0.533333:0.490632:0.008104:0.007333:0.010614:0.004475:0.003024:0.005866:0.004475:0.005125:0.009223:0.009827:0.004475:0.010311:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.009827:0.010357:0.004460:0.011188:0.011188:0.009177:0.006441:0.003417:0.004460:0.004747:0.009903:0.004551:0.004460:0.009192:0.005866:0.009827:0.004475:0.012564:0.003024:0.005125:0.009223:0.004475:0.004551:0.003024:0.004747:0.010326:0.014182:0.010311:0.003024:0.009782:0.003024:0.009223:0.004188:0.004475:0.011188:0.010614:0.008950:0.004188
carries a higher risk of hepatitis  and virological failure :@0.519045:0.520570:0.927985:0.520570:0.927985:0.504787:0.519045:0.504787:0.009782:0.010326:0.004551:0.004551:0.003024:0.009827:0.005866:0.006652:0.010326:0.006652:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.006652:0.004551:0.003024:0.005866:0.007590:0.006652:0.009903:0.004747:0.006652:0.009223:0.009827:0.010311:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188:0.002480:0.010326:0.009223:0.010357:0.006652:0.008376:0.003024:0.004551:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.010326:0.003024:0.006652:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188
when used with rifampicin. The plasma concentrations :@0.519045:0.534724:0.928000:0.534724:0.928000:0.518942:0.519045:0.518942:0.012564:0.009223:0.009827:0.009223:0.005322:0.009192:0.005866:0.009827:0.010357:0.005322:0.012564:0.003024:0.005125:0.009223:0.005322:0.004551:0.003024:0.004747:0.010326:0.014182:0.010311:0.003024:0.009782:0.003024:0.009223:0.004188:0.005337:0.006441:0.009223:0.009827:0.005322:0.010311:0.003024:0.010326:0.005866:0.014182:0.010326:0.005337:0.009782:0.009903:0.009223:0.009782:0.009827:0.009223:0.005125:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
of all boosted pIs are reduced to subtherapeutic ranges :@0.519045:0.548879:0.927985:0.548879:0.927985:0.533097:0.519045:0.533097:0.009903:0.004747:0.003613:0.010326:0.003024:0.003024:0.003629:0.010311:0.009903:0.009903:0.005866:0.005125:0.009827:0.010357:0.003613:0.008950:0.003417:0.005866:0.003613:0.010326:0.004551:0.009827:0.003613:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.003613:0.005125:0.009903:0.003613:0.005866:0.009192:0.010311:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.009827:0.009192:0.005125:0.003024:0.009782:0.003613:0.004551:0.010326:0.009223:0.010175:0.009827:0.005866:0.004188
with  rifampicin.  The  dose  of  LpV/r  should  be  doubled :@0.519045:0.563034:0.927970:0.563034:0.927970:0.547251:0.519045:0.547251:0.012564:0.003024:0.005125:0.009223:0.004188:0.002555:0.004551:0.003024:0.004747:0.010326:0.014182:0.010311:0.003024:0.009782:0.003024:0.009223:0.004188:0.004188:0.002555:0.006441:0.009223:0.009827:0.004188:0.002555:0.010357:0.009903:0.005866:0.009827:0.004188:0.002555:0.009903:0.004747:0.004188:0.002555:0.006985:0.008950:0.010614:0.006607:0.004551:0.004188:0.002555:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188:0.002555:0.010311:0.009827:0.004188:0.002555:0.010357:0.009903:0.009192:0.010311:0.003024:0.009827:0.010357:0.004188
slowly over two weeks to 800/200 mg twice a day and :@0.519045:0.577189:0.928000:0.577189:0.928000:0.561406:0.519045:0.561406:0.005866:0.003024:0.009903:0.012564:0.003024:0.008104:0.005080:0.009903:0.008376:0.009827:0.004551:0.005065:0.005125:0.012564:0.009903:0.005080:0.012564:0.009827:0.009827:0.007590:0.005866:0.005080:0.005125:0.009903:0.005065:0.008376:0.008376:0.008376:0.006607:0.008376:0.008376:0.008376:0.005095:0.014182:0.010175:0.005065:0.005125:0.012564:0.003024:0.009782:0.009827:0.005080:0.010326:0.005080:0.010357:0.010326:0.008104:0.005080:0.010326:0.009223:0.010357:0.004188
the patient monitored closely for hepatotoxicity. Con-:@0.519045:0.591343:0.923812:0.591343:0.923812:0.575561:0.519045:0.575561:0.005125:0.009223:0.009827:0.006017:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.006017:0.014182:0.009903:0.009223:0.003024:0.005125:0.009903:0.004551:0.009827:0.010357:0.006017:0.009782:0.003024:0.009903:0.005866:0.009827:0.003024:0.008104:0.006032:0.004747:0.009903:0.004551:0.006017:0.009223:0.009827:0.010311:0.010326:0.005125:0.009903:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.004188:0.006017:0.012292:0.009903:0.009223:0.005020
tinue these changes to LpV/r until two weeks after com-:@0.519045:0.605498:0.923797:0.605498:0.923797:0.589715:0.519045:0.589715:0.005125:0.003024:0.009223:0.009192:0.009827:0.003886:0.005125:0.009223:0.009827:0.005866:0.009827:0.003901:0.009782:0.009223:0.010326:0.009223:0.010175:0.009827:0.005866:0.003886:0.005125:0.009903:0.003886:0.006985:0.008950:0.010614:0.006607:0.004551:0.003886:0.009192:0.009223:0.005125:0.003024:0.003024:0.003901:0.005125:0.012564:0.009903:0.003886:0.012564:0.009827:0.009827:0.007590:0.005866:0.003901:0.010326:0.004747:0.005125:0.009827:0.004551:0.003886:0.009782:0.009903:0.014182:0.005020
pletion of TB therapy.  DTG needs to be dosed twice :@0.519045:0.619653:0.928000:0.619692:0.928000:0.603909:0.519045:0.603870:0.010311:0.003024:0.009827:0.005125:0.003024:0.009903:0.009223:0.006698:0.009903:0.004747:0.006698:0.006441:0.008678:0.006698:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.004853:0.006698:0.011249:0.006441:0.013184:0.006698:0.009223:0.009827:0.009827:0.010357:0.005866:0.006698:0.005125:0.009903:0.006698:0.010311:0.009827:0.006698:0.010357:0.009903:0.005866:0.009827:0.010357:0.006698:0.005125:0.012564:0.003024:0.009782:0.009827:-0.405122
5:@0.680994:0.614393:0.685852:0.614393:0.685852:0.605239:0.680994:0.605239:0.004858
daily when used with rifampicin.  :@0.519045:0.633847:0.762078:0.633852:0.762078:0.618069:0.519045:0.618064:0.010357:0.010326:0.003024:0.003024:0.008104:0.004188:0.012564:0.009223:0.009827:0.009223:0.004188:0.009192:0.005866:0.009827:0.010357:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.004551:0.003024:0.004747:0.010326:0.014182:0.010311:0.003024:0.009782:0.003024:0.009223:0.004188:0.004863:-0.257743
6:@0.753031:0.628553:0.757889:0.628553:0.757889:0.619399:0.753031:0.619399:0.004858
Hepatitis b co-infection:@0.533327:0.648006:0.694133:0.648006:0.694133:0.631508:0.533327:0.631508:0.009979:0.009374:0.009676:0.009676:0.004233:0.003326:0.004233:0.003326:0.006350:0.003296:0.008467:0.003296:0.009374:0.009374:0.006048:0.003326:0.008769:0.003931:0.009374:0.009374:0.004233:0.003326:0.009374:0.009071
 – All HIV-infected patients should :@0.693831:0.648006:0.927980:0.648006:0.927980:0.632224:0.693831:0.632224:0.003251:0.007257:0.003251:0.010886:0.002721:0.002721:0.003251:0.010024:0.003115:0.010311:0.004717:0.002721:0.008920:0.004445:0.009525:0.009480:0.004823:0.009525:0.010054:0.003251:0.010009:0.010024:0.004823:0.002721:0.009525:0.008920:0.004823:0.005564:0.003251:0.005564:0.008920:0.009601:0.008890:0.002721:0.010357:0.004188
be screened for co-infection with hepatitis B. The ART regi-:@0.519040:0.662161:0.923852:0.662161:0.923852:0.646378:0.519040:0.646378:0.010009:0.009525:0.003689:0.005564:0.009480:0.004248:0.009525:0.009525:0.008920:0.009525:0.010054:0.003689:0.004445:0.009601:0.004248:0.003689:0.009480:0.009601:0.004717:0.002721:0.008920:0.004445:0.009525:0.009480:0.004823:0.002721:0.009601:0.008920:0.003689:0.012262:0.002721:0.004823:0.008920:0.003689:0.008920:0.009525:0.010009:0.010024:0.004823:0.002721:0.004823:0.002721:0.005564:0.003689:0.008376:0.003886:0.003689:0.006138:0.008920:0.009525:0.003689:0.010886:0.008875:0.006138:0.003689:0.004248:0.009525:0.009873:0.002721:0.005020
men should include TDF and 3TC (or FTC). NVp should be :@0.519040:0.676316:0.928055:0.676316:0.928055:0.660533:0.519040:0.660533:0.013879:0.009525:0.008920:0.004626:0.005564:0.008920:0.009601:0.008890:0.002721:0.010054:0.004626:0.002721:0.008920:0.009480:0.002721:0.008890:0.010054:0.009525:0.004626:0.006138:0.010946:0.007030:0.004626:0.010024:0.008920:0.010054:0.004626:0.008074:0.006138:0.011989:0.004626:0.005277:0.009601:0.004248:0.004626:0.007030:0.006138:0.011989:0.005277:0.003886:0.004611:0.010886:0.010311:0.008648:0.004626:0.005564:0.008920:0.009601:0.008890:0.002721:0.010054:0.004626:0.010009:0.009827:0.004188
avoided in patients with hepatitis B co-infection.:@0.519040:0.690470:0.855832:0.690470:0.855832:0.674688:0.519040:0.674688:0.010024:0.008074:0.009601:0.002721:0.010054:0.009525:0.010054:0.003886:0.002721:0.008920:0.003886:0.010009:0.010024:0.004823:0.002721:0.009525:0.008920:0.004823:0.005564:0.003886:0.012262:0.002721:0.004823:0.008920:0.003886:0.008920:0.009525:0.010009:0.010024:0.004823:0.002721:0.004823:0.002721:0.005564:0.003886:0.008376:0.003886:0.009480:0.009601:0.004717:0.002721:0.008920:0.004445:0.009525:0.009480:0.004823:0.002721:0.009601:0.008920:0.004188
5,6:@0.855527:0.685191:0.867321:0.685191:0.867321:0.676037:0.855527:0.676037:0.004683:0.002254:0.004858
If patients meet criteria for switching to a second-line :@0.533333:0.704649:0.927970:0.704649:0.927970:0.688867:0.533333:0.688867:0.003417:0.004747:0.004581:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004581:0.014182:0.009827:0.009827:0.005125:0.004581:0.009782:0.004551:0.003024:0.005125:0.009827:0.004551:0.003024:0.010326:0.004581:0.004747:0.009903:0.004551:0.004581:0.005866:0.012564:0.003024:0.005125:0.009782:0.009223:0.003024:0.009223:0.010175:0.004581:0.005125:0.009903:0.004581:0.010326:0.004581:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005020:0.003024:0.003024:0.009223:0.009827:0.004188
ART regimen to treat their HIV, TDF and 3TC/FTC should :@0.519045:0.718804:0.928000:0.718804:0.928000:0.703022:0.519045:0.703022:0.011188:0.009177:0.006441:0.004944:0.004551:0.009827:0.010160:0.003024:0.014182:0.009827:0.009223:0.004959:0.005125:0.009903:0.004959:0.005125:0.004551:0.009827:0.010326:0.005125:0.004959:0.005125:0.009223:0.009827:0.003024:0.004551:0.004959:0.010326:0.003417:0.010614:0.004188:0.004959:0.006441:0.011249:0.007333:0.004959:0.010326:0.009223:0.010357:0.004959:0.008376:0.006441:0.012292:0.006607:0.007333:0.006441:0.012292:0.004959:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188
also be included, as an interruption  has been  asso-:@0.519045:0.732959:0.923812:0.732959:0.923812:0.717176:0.519045:0.717176:0.010326:0.003024:0.005866:0.009903:0.008270:0.010311:0.009827:0.008270:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.010357:0.004188:0.008270:0.010326:0.005866:0.008270:0.010326:0.009223:0.008270:0.003024:0.009223:0.005125:0.009827:0.004551:0.004551:0.009192:0.010311:0.005125:0.003024:0.009903:0.009223:0.004188:0.004067:0.009223:0.010326:0.005866:0.008270:0.010311:0.009827:0.009827:0.009223:0.004188:0.004067:0.010326:0.005866:0.005866:0.009903:0.005020
ciated  with  life-threatening  hepatitis  flares.  In  patients :@0.519045:0.747114:0.927985:0.747114:0.927985:0.731331:0.519045:0.731331:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.004188:0.002434:0.012564:0.003024:0.005125:0.009223:0.004188:0.002419:0.003024:0.003024:0.004747:0.009827:0.005020:0.005125:0.009223:0.004551:0.009827:0.010326:0.005125:0.009827:0.009223:0.003024:0.009223:0.010175:0.004188:0.002419:0.009223:0.009827:0.010311:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188:0.002434:0.003666:0.003666:0.010326:0.004551:0.009827:0.005866:0.004188:0.004188:0.002419:0.003417:0.009223:0.004188:0.002419:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
with renal dysfunction,  TDF may be considered with :@0.519045:0.761268:0.927985:0.761268:0.927985:0.745486:0.519045:0.745486:0.012564:0.003024:0.005125:0.009223:0.008391:0.004551:0.009827:0.009207:0.010326:0.003024:0.008391:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.004188:0.006441:0.011249:0.007333:0.008391:0.014182:0.010326:0.008104:0.008391:0.010311:0.009827:0.008391:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.008391:0.012564:0.003024:0.005125:0.009223:0.004188
dosing based on creatinine clearance. If renal function :@0.519045:0.775423:0.928000:0.775423:0.928000:0.759640:0.519045:0.759640:0.010357:0.009903:0.005866:0.003024:0.009223:0.010175:0.004324:0.010311:0.010326:0.005866:0.009827:0.010357:0.004339:0.009903:0.009223:0.004324:0.009782:0.004551:0.009827:0.010326:0.005125:0.003024:0.009223:0.003024:0.009223:0.009827:0.004324:0.009782:0.003024:0.009827:0.010326:0.004551:0.010326:0.009223:0.009782:0.009827:0.004188:0.004324:0.003417:0.004747:0.004324:0.004551:0.009827:0.009223:0.010326:0.003024:0.004324:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188
worsens with TDF, 3TC monotherapy with or without pe-:@0.519045:0.789578:0.923812:0.789578:0.923812:0.773795:0.519045:0.773795:0.012564:0.009903:0.004551:0.005866:0.009827:0.009223:0.005866:0.004536:0.012564:0.003024:0.005125:0.009223:0.004551:0.006441:0.011249:0.007333:0.004188:0.004536:0.008376:0.006441:0.012292:0.004551:0.014182:0.009903:0.009223:0.009903:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004536:0.012564:0.003024:0.005125:0.009223:0.004551:0.009903:0.004551:0.004536:0.012564:0.003024:0.005125:0.009223:0.009903:0.009192:0.005125:0.004536:0.010311:0.009827:0.005020
gylated interferon-alpha should be considered if avail-:@0.519045:0.803733:0.923812:0.803733:0.923812:0.787950:0.519045:0.787950:0.010175:0.008104:0.003024:0.010326:0.005125:0.009827:0.010357:0.005216:0.003024:0.009223:0.005125:0.009827:0.004551:0.004747:0.009812:0.004551:0.009903:0.009223:0.005020:0.010326:0.003024:0.010311:0.009223:0.010326:0.005216:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005216:0.010311:0.009827:0.005216:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.005216:0.003024:0.004747:0.005216:0.010326:0.008376:0.010326:0.003024:0.003054:0.005020
able under specialist care.  :@0.519045:0.817887:0.722147:0.817926:0.722147:0.802144:0.519045:0.802105:0.010326:0.010311:0.003024:0.009827:0.004188:0.009192:0.009223:0.010357:0.009827:0.004551:0.004188:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.005866:0.005125:0.004188:0.009782:0.010326:0.004551:0.009827:0.004188:0.004861:-0.458862
5:@0.713099:0.812628:0.717958:0.812628:0.717958:0.803474:0.713099:0.803474:0.004858
malaria:@0.533326:0.832081:0.588964:0.832081:0.588964:0.815583:0.533326:0.815583:0.013607:0.009979:0.003629:0.009979:0.004838:0.003629:0.009979
 – In uncomplicated malaria, patients should :@0.588964:0.832081:0.927978:0.832081:0.927978:0.816298:0.588964:0.816298:0.005700:0.007560:0.005700:0.003417:0.009223:0.005700:0.009192:0.009223:0.009782:0.009903:0.014182:0.010311:0.003024:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.005700:0.014182:0.010326:0.003024:0.010326:0.004551:0.003024:0.010326:0.004188:0.005715:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005715:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188
be treated with artemether-lumefantrine (Coartem ). It :@0.519038:0.846236:0.927992:0.846245:0.927992:0.830463:0.519038:0.830453:0.010311:0.009827:0.004611:0.005125:0.004551:0.009827:0.010326:0.005125:0.009827:0.010357:0.004611:0.012564:0.003024:0.005125:0.009223:0.004611:0.010326:0.004551:0.005125:0.009827:0.014182:0.009827:0.005125:0.009223:0.009827:0.004551:0.005020:0.003024:0.009177:0.014182:0.009827:0.004747:0.010326:0.009223:0.005125:0.004551:0.003024:0.009223:0.009827:0.004611:0.005579:0.012292:0.009903:0.010326:0.004551:0.005125:0.009827:0.014182:0.006561:0.005579:0.004188:0.004611:0.003417:0.005125:-0.701791
®:@0.894333:0.840947:0.900883:0.840947:0.900883:0.831793:0.894333:0.831793:0.006550
is safe with NNRTIs. Boosted pIs increase the plasma con-:@0.519053:0.860400:0.923819:0.860400:0.923819:0.844618:0.519053:0.844618:0.003024:0.005866:0.003477:0.005866:0.010326:0.004747:0.009827:0.003477:0.012564:0.003024:0.005125:0.009223:0.003477:0.011188:0.011188:0.009162:0.006441:0.003417:0.005866:0.004188:0.003462:0.008678:0.009903:0.009903:0.005866:0.005125:0.009827:0.010357:0.003477:0.008950:0.003417:0.005866:0.003477:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.003477:0.005125:0.009223:0.009827:0.003462:0.010311:0.003024:0.010326:0.005866:0.014182:0.010326:0.003477:0.009782:0.009903:0.009223:0.005020
centrations of lumefantrine, but a dose reduction is not :@0.519053:0.874555:0.928022:0.874555:0.928022:0.858772:0.519053:0.858772:0.009782:0.009827:0.009223:0.005125:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004581:0.009903:0.004747:0.004581:0.003024:0.009192:0.014182:0.009827:0.004747:0.010326:0.009223:0.005125:0.004551:0.003024:0.009223:0.009827:0.004188:0.004581:0.010311:0.009192:0.005125:0.004581:0.010326:0.004581:0.010357:0.009903:0.005866:0.009827:0.004581:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004581:0.003024:0.005866:0.004596:0.009223:0.009903:0.005125:0.004188
recommended, as the toxicity threshold of lumefantrine :@0.519053:0.888710:0.928007:0.888710:0.928007:0.872927:0.519053:0.872927:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.003795:0.010326:0.005866:0.003810:0.005125:0.009223:0.009827:0.003810:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.003810:0.005125:0.009223:0.004551:0.009827:0.005866:0.009223:0.009903:0.003024:0.010357:0.003795:0.009903:0.004747:0.003810:0.003024:0.009192:0.014182:0.009827:0.004747:0.010326:0.009223:0.005125:0.004551:0.003024:0.009223:0.009827:0.004188
seems to be high. patients with severe malaria should :@0.519053:0.902864:0.928007:0.902864:0.928007:0.887082:0.519053:0.887082:0.005866:0.009827:0.009827:0.014182:0.005866:0.006153:0.005125:0.009903:0.006138:0.010311:0.009827:0.006153:0.009223:0.003024:0.010175:0.009223:0.004188:0.006153:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006138:0.012564:0.003024:0.005125:0.009223:0.006153:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.006153:0.014182:0.010326:0.003024:0.010326:0.004551:0.003024:0.010326:0.006153:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188
be referred for specialist care to receive intravenous ar-:@0.519053:0.917019:0.923804:0.917019:0.923804:0.901236:0.519053:0.901236:0.010311:0.009827:0.003976:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.009827:0.010357:0.003961:0.004747:0.009903:0.004551:0.003961:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.005866:0.005125:0.003991:0.009782:0.010326:0.004551:0.009827:0.003961:0.005125:0.009903:0.003961:0.004551:0.009827:0.009782:0.009827:0.003024:0.008376:0.009827:0.003961:0.003024:0.009223:0.005125:0.004551:0.010326:0.008376:0.009827:0.009223:0.009903:0.009192:0.005866:0.003961:0.010326:0.004551:0.005020
tesunate. Quinine should be avoided in patients receiv-:@0.519053:0.931174:0.923819:0.931174:0.923819:0.915391:0.519053:0.915391:0.005125:0.009827:0.005866:0.009192:0.009223:0.010326:0.005125:0.009827:0.004188:0.003991:0.013169:0.009192:0.003024:0.009223:0.003024:0.009223:0.009827:0.004007:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004007:0.010311:0.009827:0.004007:0.010326:0.008376:0.009903:0.003024:0.010357:0.009827:0.010357:0.004007:0.003024:0.009223:0.004007:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004007:0.004551:0.009827:0.009782:0.009827:0.003024:0.008376:0.005020
ing pIs or NNRTIs. :@0.519053:0.945328:0.642378:0.945328:0.642378:0.929546:0.519053:0.929546:0.003024:0.009223:0.010175:0.004188:0.008950:0.003417:0.005866:0.004188:0.009903:0.004551:0.004188:0.011188:0.011188:0.009177:0.006441:0.003417:0.005866:0.004188:0.004188